Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study-Reference-Cited by-同舟云学术

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Published:2017-09-15 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

van der Hiel Bernies^ORCID, ,Haanen John B.A.G.,Stokkel Marcel P.M.,Peeper Daniel S.,Jimenez Connie R.,Beijnen Jos H.,van de Wiel Bart A.,Boellaard Ronald,van den Eertwegh Alfons J.M.

Funder

F. Hoffman-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3626-5.pdf

Reference60 articles.

1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–89.

2. IKNL Incidence Data. Netherlands Compehensive Cancer Organisation, the Netherlands. 2015. http://www.cijfersoverkanker.nl . Accessed 17 Dec 2015.

3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.